ICATIBANT ACETATE (icatibant) by Teva is b2 receptor, with an affinity similar to bradykinin. Approved for acute attacks of hereditary angioedema (hae) in adults 18 years of age, older. First approved in 2019.
Drug data last refreshed 18h ago
B2 receptor, with an affinity similar to bradykinin. Hereditary angioedema is caused by an absence or dysfunction of C1-esterase-inhibitor, a key regulator of the Factor XII/kallikrein proteolytic cascade that leads to bradykinin production. Bradykinin is a vasodilator which is thought to be…
Worked on ICATIBANT ACETATE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home
A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema
A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema